Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study

Gilead Sciences, Inc.

today announced full Phase 3 clinical trial results from pivotal Study 102 demonstrating that the Quad, a once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection, is non-inferior to Atripla^ after 48 weeks of therapy in treatment-naïve adults. Atripla is currently the most-prescribed HIV treatment regimen in the United States. The Study 102 findings were presented today in an oral session (Abstract #101) at the 19^th Conference on Retroviruses and Opportunistic Infections (CROI 2012) taking place in Seattle.